These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15771557)

  • 1. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.
    Gilli F; Marnetto F; Stefanuto G; Rinaldi V; Farinazzo F; Malucchi S; Capobianco M; Caldano M; Sala A; Bertolotto A
    Mol Diagn; 2004; 8(3):185-94. PubMed ID: 15771557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.
    Bertolotto A; Gilli F; Sala A; Audano L; Castello A; Magliola U; Melis F; Giordana MT
    J Immunol Methods; 2001 Oct; 256(1-2):141-52. PubMed ID: 11516761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
    Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.
    Pachner A; Narayan K; Price N; Hurd M; Dail D
    Mol Diagn; 2003; 7(1):17-25. PubMed ID: 14529316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
    Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
    J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F; Schibeci S; Heard R; Stewart G; Booth D
    J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
    Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.
    Serana F; Imberti L; Amato MP; Comi G; Gasperini C; Ghezzi A; Martinelli V; Provinciali L; Rottoli MR; Sotgiu S; Stecchi S; Vecchio M; Zaffaroni M; Cordioli C; Capra R
    PLoS One; 2014; 9(4):e94794. PubMed ID: 24733382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.
    Capra R; Sottini A; Cordioli C; Serana F; Chiarini M; Caimi L; Padovani A; Bergamaschi R; Imberti L
    J Neuroimmunol; 2007 Sep; 189(1-2):102-10. PubMed ID: 17619058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
    Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
    Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.
    Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Capobianco M; Bertolotto A
    Mult Scler; 2006 Feb; 12(1):47-57. PubMed ID: 16459719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).
    Pachner AR; Bertolotto A; Deisenhammer F
    Neurology; 2003 Nov; 61(9 Suppl 5):S24-6. PubMed ID: 14610107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.
    Libertinova J; Meluzinova E; Matoska V; Zajac M; Kovarova I; Havrdova E; Horakova D; Tomek A; Marusic P; Bojar M
    Brain Behav; 2017 Mar; 7(3):e00644. PubMed ID: 28293479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience.
    Zanotti C; Ghidini C; Lamorgese C; Caimi L; Capra R; Imberti L
    Clin Chem Lab Med; 2010 Sep; 48(9):1235-8. PubMed ID: 20678029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients.
    Cakal B; Uygunoglu U; Saip S; Altintas A; Siva A; Badur S
    J Immunoassay Immunochem; 2014; 35(4):398-411. PubMed ID: 24547871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against interferon-beta in multiple sclerosis.
    Aarskog NK; Marøy T; Myhr KM; Vedeler CA
    J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
    Scagnolari C; Duda P; Bagnato F; De Vito G; Alberelli A; Lavolpe V; Girardi E; Durastanti V; Trojano M; Kappos L; Antonelli G
    J Neurol; 2007 May; 254(5):597-604. PubMed ID: 17420930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.